Most pharma brands are sitting on the exact content an answer engine wants, and the engine never sees it.
Inside the system of record there is a library of approved modules: the indication phrased the way MLR cleared it, the safety language down to the clause, the efficacy claim with its reference attached, the fair balance, the ISI. Every piece is reviewed, version-controlled, and traceable. It is the cleanest, most authoritative description of the drug that exists anywhere. And when a clinician asks ChatGPT, Perplexity, or Google AI Overviews what the drug treats, none of it shows up. The machine answers from a press release, a patient forum, a competitor's comparison page, and a conference abstract from three years ago. The approved content lost the answer to sources the brand does not control and would never have written.
That is the gap. It is not that the approved content is wrong. It is that the approved content is unreachable, unstructured, and unmeasured, so the machine routes around it. Closing the gap is a three-part job: make approved content retrievable, measure which modules the machine actually cites, and feed the gaps back into the system of record. None of it requires throwing out the system of record. It requires teaching that system to speak to the machine.
Why the approved library loses to a forum post
Answer engines do not reward authority the way a regulator would define it. They reward retrievability and structure. Research from Princeton, Georgia Tech, and the Allen Institute for AI tested content modifications across thousands of queries and found that adding citations, quotations, and statistics boosted a source's visibility in AI answers by over 40 percent. The machine prefers content that states a clear fact, attaches a source, and is easy to lift as a standalone passage.
Now look at how approved pharma content lives. It lives as a PDF detail aid, a slide in a CLM deck, a claim locked inside an approved asset in the digital asset management system. It is built to be presented by a human, not parsed by a retriever. The clause that would make a perfect citation, "indicated for X in adults who have failed Y," is rendered as an image in a banner, buried on page nine of a leave-behind, or sitting in a module the public internet cannot reach at all. The content is authoritative and invisible at the same time. A forum post that says the same thing in plain, indexed, quotable text beats it every time, because the engine can actually retrieve and lift the forum post.
There is a second mechanism working against the brand. Answer engines lean heavily on conventional retrieval rank. Industry analysis of AI citations has found that the large majority of sources cited in AI Overviews come from the organic top ten results, and citation odds fall sharply with every position lost. If the approved content is not retrievable as clean web text, it is not in the top ten, so it is not in the candidate pool the model draws from. Saying nothing the machine can read is the same as saying nothing.
The system of record is the answer, not the obstacle
The instinct, when the approved library is invisible, is to stand up a separate content operation for AI. That is the wrong move. The system of record, whether that is Veeva PromoMats or another DAM, is exactly where the approved, clause-cited, MLR-signed modules already live with their traceability intact. Veeva positions PromoMats as "one library for approved content and assets, delivering simple content re-use with traceability and compliance", and reports a 15 percent increase in content reuse and 25 percent faster content to market when MLR review and DAM are combined. The modular content already inside that system is the raw material for everything an answer engine wants. The job is not to replace it. The job is to integrate with it so the approved module becomes the source the machine retrieves.
This is where modular content stops being only an efficiency story and becomes a visibility story. A brand that has already broken its message into approved, reusable modules, copy, claims, references, disclaimers, has done most of the structuring work that GEO requires. Each module is a clause-cited, attributable fact: precisely the shape the Princeton study found gets cited. The modular content investment that pharma made for faster reviews turns out to be the same investment that makes content retrievable by the machine. The payoff stacks.
Modular content already pays for itself on the review side. Industry reports describe early adopters cutting content creation time and review cycles substantially, with a large share of modular assets clearing MLR in a single cycle. Use the same approved modules as the source the answer engines read, and the brand gets a second return on the same approved core: faster approvals on the inside, and a fighting chance at the citation on the outside.
Three moves to close the gap
1. Make the approved module retrievable, as structured text
Take the modules that should win the answer, the approved indication, the mechanism, the key safety statements, and publish them as clean, structured, machine-legible web content, not as an image inside a banner or a slide inside a deck. Mark up the entity, the claim, and the reference so a retriever can resolve what the content is about. Structured data acts as "a high-confidence signal layer during the retrieval and ranking phase" that reduces ambiguity and makes a model more confident in citing the page. The content is already approved. The work is rendering it in the form the machine can read, sourced from the same module so it stays in sync with what MLR cleared.
2. Measure which modules the machine actually cites
You cannot close a gap you cannot see. For the questions your HCPs and patients actually ask, run them across the engines your audience uses and record, per answer, three things: is the brand mentioned, which source did the engine cite, and is the cited statement one of your approved modules or something third party. That last column is the real finding. It tells you exactly which approved modules are winning the citation and which are being beaten by a forum, a competitor, or a stale abstract. Module-level measurement turns a vague worry about AI into a ranked list of which approved clauses to push.
3. Feed the gaps back into the system of record
When the measurement shows a question where a third-party source is winning, that is a content gap with an address. Route it back to the team that owns the module. Sometimes the approved module exists but is not retrievable, so it needs publishing in structured form. Sometimes the module does not exist yet, so it needs authoring and an MLR pass. Either way the loop closes inside the system of record, where the change is traceable and the new module is reusable everywhere else. The outside signal, what the machine cites, becomes a prioritized backlog for the inside system, what the brand approves and publishes.
A worked example: Varigel
Varigel is a fictional brand approved for one narrow indication, with a known contraindication for patients on a common comorbidity medication. The approved library is immaculate. The indication, the contraindication, and the pivotal efficacy claim each exist as a clause-cited, MLR-signed module in the DAM.
Run the audit. Ask five engines what Varigel is used for and which sources they cite. The pattern that comes back is the gap made visible. For the approved indication, two engines cite the label cleanly, but three cite a third-party drug-information page that paraphrases the indication slightly loosely. For the contraindication, only one engine surfaces it at all, and it cites a patient forum, not the brand, because the approved safety module lives only inside a CLM deck the retriever cannot reach. For the efficacy claim, every engine cites a press summary rather than the approved module with its reference.
Now the three moves have addresses. The approved indication module gets published as structured text, so the brand's clean clause enters the candidate pool the engines draw from. The contraindication module, which existed but was trapped in a deck, gets rendered as retrievable web content, so the safety statement competes with the forum instead of ceding the answer to it. The efficacy module gets published with its reference attached, the form the Princeton study found tends to get cited. Re-run the audit in a few weeks and you can track whether the citation column moves: with the approved clause now reachable and structured, those modules become more likely to be cited, though no one can guarantee what any given engine quotes. The brand did not write new claims. It made the claims it had already approved reachable, then measured the result and fed the gaps back.
The takeaway
The approved library is the brand's best asset and its most invisible one. Answer engines cite what is retrievable, structured, and attributable, and approved pharma modules are all three the moment they leave the deck and enter machine-legible content. Treat the system of record as the source of truth it already is, publish the modules the machine should read, measure which ones it actually cites, and route the gaps back. Content reuse is the payoff that funds the whole loop: the same approved core that clears MLR faster is the core you give the machine the best chance to repeat.
Juncture sits on that seam. It reads the approved modules from your system of record, measures which of them the answer engines cite versus where a third-party source is winning, and hands back a ranked list of gaps to close, each one traceable to the module that should have won. Bring one brand and the questions your audience actually asks. We will show you, module by module, what the machine cites today and which approved clauses are losing answers they should own.
Sources
- Aggarwal et al., "GEO: Generative Engine Optimization," Princeton University, Georgia Tech, Allen Institute for AI, and IIT Delhi, KDD 2024. arxiv.org
- Veeva, "Veeva PromoMats Digital Asset Management." veeva.com
- SERPs.io, "Schema Markup for AI: Structured Data That Helps LLMs Understand You." serps.io
- Viseven, "Modular Content for Pharma Marketing and Life Science." viseven.com